

Interpace Pharma Solutions is a leader in enabling precision medicine for immuno-oncology and genomic medicine through diagnostics, molecular markers, and data solutions.

Interpace Pharma Solutions (IPS) provides laboratory services supporting clinical trials and advanced diagnostic development across immuno-oncology, hematology, and solid tumors. Our scientific, medical, and regulatory experts help our biopharma and diagnostic clients accelerate their clinical development programs. Through our extensive technology portfolio and agile approach, we provide a broad suite of applications in support of our industry partners.

IPS's Cytogenetic Services

IPS offers a complete cytogenetics laboratory with karyotyping and FISH capabilities. It is staffed with highly experienced professionals, with an average of 15 years of experience in cytogenetics. IPS's state-of-the-art cytogenetics laboratory is equipped with automated FISH and metaphase capture stations.

Our staff is highly experienced in the various cytogenetic techniques required for handling a variety of specimen types including bone marrow (BM), peripheral blood (PB), lymph node, cerebrospinal fluid, pleural effusion, short-term cultures, etc. Our laboratory is equipped to perform FISH analysis for 50+ probes on hematological malignancies. We are one of the elite centers for performing CD138 enriched FISH for multiple myeloma as a result of our extensive collaboration with academic and commercial institutions.

We perform both manual and automated processing on formalin-fixed paraffin-embedded (FFPE) solid tumor samples, including breast, lung, bladder, brain cancers, and others. Most of the manual processing of FFPEs includes FDA-cleared ALK FISH for lung carcinoma and Pathvysion for breast carcinoma. In addition, we have a proprietary FISH assay (FHACTION) for cervical cancer which can detect precancerous lesions that progress to cancer.

This is a representative listing of available test offerings.
Interpace Pharma Solutions builds custom solutions to meet client specifications.

Heme Malignancies

Acute Lymphocytic Leukemia (B-ALL)

11q23 (MLL-Break Apart)
9p21 (CDKN2A[p16])
t(9;22) (BCR/ABL/ASS)
t(12;21) (ETV6/RUNX1)
CEP 4, 10, 17
17p13 (TP53)

Acute Lymphocytic Leukemia (T-ALL)

14q11 (TCR-Alpha/Delta Break Apart)
t(1;19) PBX1-TCF3(E2A)
4q12/D10Z1/D17Z1

Acute Myeloid Leukemia (AML)

11q23 (MLL-Break Apart)
t(8;21) (ETO/AML1) [M2]
t(15;17) (PML/RARA) [M3]
Inv(16) (CBFB-Break Apart) [M4, Eos]

Anaplastic Large Cell Lymphoma

2q23 (ALK-Break Apart)

BM Transplant Monitoring

CEP X/Y

Chronic Lymphocytic Leukemia (CLL)

- 11q22.3 (ATM)/17p13 (TP53)
- CEP12/13q14 (D13S319)/13q34
- CEP6/6q23 (c-MYB)
- t(11;14) (CCND1/IGH)

Chronic Myelogenous Leukemia (CML)

t(9;22) (BCR/ABL/ASS)

• Denotes an FDA-cleared or FDA-approved test. These *in vitro* diagnostic test kits are provided by a third-party manufacturer. Additional details and indications for use can be provided upon request.

Heme Malignancies (continued)

CML in Blast Crisis

t(9;22) (BCR/ABL/ASS)
 17p13 (TP53)
 CEP8

Multiple Myeloma (MM)

1p (CDKN2C)/1q (CKS1B)
 17p13 (TP53)
 t(4;14) (FGFR3/IGH)
 t(11;14) (CCND1/IGH)
 t(14;16) (IGH/MAF)
 13q14/13q34
 D5S23/D5S71/CEP9/CEP15
 IGH-Break Apart
 t(14;20) (IGH/MAFB)
 t(6;14) (CCND3/IGH)
 CEP7/CEP11

MM CD138 - Plasma Cell Purification

1p/1q
 17p13 (TP53)
 IGH-Break Apart*
 D5S23/D5S71/CEP9/CEP15**
 13q14/13q34

* if positive reflex to: CCND1/IGH; FGFR3/IGH; IGH/MAF;
 IGH/MAFB; CCND3/IGH

** if positive reflex to: CEP7/CEP11

Myelodysplastic Syndrome (MDS)

5q15.2/5q31
 CEP7/7q31
 CEP8
 20q12
 11q23 (MLL-Break Apart)

Myeloproliferative Neoplasms (MPN)

4q12 (FIP1L1/CHIC2/PDGFR4)
 5q33 (PDGFRB-Break Apart)
 BCR/ABL (BCR/ABL/ASS)
 FGFR1-Break Apart

Non-Hodgkin's Lymphoma (NHL)

t(8;14) (MYC/IGH)
 3q27 (BCL6-Break Apart)
 t(14;18) (IGH/BCL2)
 t(11;14) (CCND1/IGH)
 MALT1-Break Apart
 IGH-Break Apart
 cMYC-Break Apart
 BCL2-Break Apart

Solid Tumor

Brain Cancer

1p/19q deletion
 PTEN

Breast Cancer

• PathVysion[®] (HER2/neu)
 EGFR

Gastric Cancer

HER2 Amplification

Lung Cancer

• ALK-Break Apart
 MET
 RET
 ROS1
 EGFR

• Denotes an FDA-cleared or FDA-approved test. These *in vitro* diagnostic test kits are provided by a third-party manufacturer. Additional details and indications for use can be provided upon request.